» Articles » PMID: 33934105

Enhancer Rewiring in Tumors: an Opportunity for Therapeutic Intervention

Overview
Journal Oncogene
Date 2021 May 2
PMID 33934105
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Enhancers are cis-regulatory sequences that fine-tune expression of their target genes in a spatiotemporal manner. They are recognized by sequence-specific transcription factors, which in turn recruit transcriptional coactivators that facilitate transcription by promoting assembly and activation of the basal transcriptional machinery. Their functional importance is underscored by the fact that they are often the target of genetic and nongenetic events in human disease that disrupt their sequence, interactome, activation potential, and/or chromatin environment. Dysregulation of transcription and addiction to transcriptional effectors that interact with and modulate enhancer activity are common features of cancer cells and are amenable to therapeutic intervention. Here, we discuss the current knowledge on enhancer biology, the broad spectrum of mechanisms that lead to their malfunction in tumor cells, and recent progress in developing drugs that efficaciously target their dependencies.

Citing Articles

Genetic coupling of enhancer activity and connectivity in gene expression control.

Ray-Jones H, Sung C, Chan L, Haglund A, Artemov P, Della Rosa M Nat Commun. 2025; 16(1):970.

PMID: 39870618 PMC: 11772589. DOI: 10.1038/s41467-025-55900-3.


Active enhancers: recent research advances and insights into disease.

Zhang J, Wang Q, Liu J, Duan Y, Liu Z, Zhang Z Biol Direct. 2024; 19(1):112.

PMID: 39533395 PMC: 11556110. DOI: 10.1186/s13062-024-00559-x.


Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma.

Abatti L, Lado-Fernandez P, Huynh L, Collado M, Hoffman M, Mitchell J Nucleic Acids Res. 2023; 51(19):10109-10131.

PMID: 37738673 PMC: 10602899. DOI: 10.1093/nar/gkad734.


Nuclear Mechanisms Involved in Endocrine Resistance.

Dittmer J Front Oncol. 2021; 11:736597.

PMID: 34604071 PMC: 8480308. DOI: 10.3389/fonc.2021.736597.


Transcriptional enhancers and their communication with gene promoters.

Ray-Jones H, Spivakov M Cell Mol Life Sci. 2021; 78(19-20):6453-6485.

PMID: 34414474 PMC: 8558291. DOI: 10.1007/s00018-021-03903-w.


References
1.
Frankel N, Davis G, Vargas D, Wang S, Payre F, Stern D . Phenotypic robustness conferred by apparently redundant transcriptional enhancers. Nature. 2010; 466(7305):490-3. PMC: 2909378. DOI: 10.1038/nature09158. View

2.
Kim T, Hemberg M, Gray J, Costa A, Bear D, Wu J . Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010; 465(7295):182-7. PMC: 3020079. DOI: 10.1038/nature09033. View

3.
De Santa F, Barozzi I, Mietton F, Ghisletti S, Polletti S, Tusi B . A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol. 2010; 8(5):e1000384. PMC: 2867938. DOI: 10.1371/journal.pbio.1000384. View

4.
Kagey M, Newman J, Bilodeau S, Zhan Y, Orlando D, van Berkum N . Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010; 467(7314):430-5. PMC: 2953795. DOI: 10.1038/nature09380. View

5.
Calo E, Wysocka J . Modification of enhancer chromatin: what, how, and why?. Mol Cell. 2013; 49(5):825-37. PMC: 3857148. DOI: 10.1016/j.molcel.2013.01.038. View